不同分子分型乳腺癌组织中趋化因子CXCL12及其受体CXCR4和CXCR7的表达及临床意义

Expression of chemokine CXCL12 and its receptor(CXCR4 and CXCR7) in different molecular subtypes of human breast carcinoma and the clinical significance

目的:探讨趋化因子CXCL12及其受体CXCR4和CXCR7在不同分子分型乳腺癌组织中的表达及临床意义。方法:应用实时定量PCR检查80例不同分子分型乳腺癌组织中的趋化因子CXCL12 mRNA及其受体CXCR4和CXCR7 mRNA的表达,采用免疫组织化学技术检测160例不同分子分型乳腺癌细胞组织中趋化因子CXCL12蛋白及其受体CXCR4和CXCR7蛋白的表达,并分析它们在不同分子分型乳腺癌中的表达差异。结果:CXCL12 mRNA及其受体CXCR4和CXCR7 mRNA在Luminal A和Luminal B型中表达无差异,在HER-2过表达型和三阴性乳腺癌(triple negative breast cancer,TNBC)两个类型之间的表达也无差异,但三者在HER-2过表达型和TNBC中的表达明显高于Luminal A和Luminal B型(均P<0.05);CXCL12蛋白、CXCR4蛋白和CXCR7蛋白在HER-2过表达型和TNBC中的阳性表达率均明显高于Luminal A和Luminal B型(均P<0.05),但在Luminal A和Luminal B之间及HER-2过表达型和TNBC之间的表达无差异。结论:趋化因子CXCL12及其受体CXCR4和CXCR7在HER-2过表达型乳腺癌和TNBC组织中高表达,可能与该类型乳腺癌预后较差有关,抑制其表达可为该类乳腺癌的治疗提供重要途径。

Objective： To study the expressions and the clinical significance of chemokine CXCL12 and its receptor CXCR4, CXCR7 in the human breast carcinoma （BC） with different molecular subtypes. Methods： The mRNA expressions of CXCL12, CXCR4 and CXCR7 in tissues from 80 patientswith different molecular subtype of BC were measured by qRT-PCR. Xhe protein expressions of CXCL12, CXCR4 and CXCR7 in paraffin-embedded samples from 160 patients with different molecular subtypes were detected by immunohistochemical staining. Results： ]lae mRNA expression levels of CXCL12, CXCR4 and CXCR7 in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues （all P〈0.05）, but their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues. Xhe positive expression rates of CXCL12 protein in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues （all P〈0.05）, while their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues. Conclusion： High expressions of the gene CXCL12 and its receptor CXCR4 and CXCR7 in HER- 2 positive BC and TNBC may be closely associated with their poor prognosis. Inhibition of their expressions in HER-2 positive BC and TNBC may provide a strategy for treating BC in clinic.